Sarah Bernstein

674 total citations
19 papers, 538 citations indexed

About

Sarah Bernstein is a scholar working on Immunology, Molecular Biology and Oncology. According to data from OpenAlex, Sarah Bernstein has authored 19 papers receiving a total of 538 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Immunology, 7 papers in Molecular Biology and 7 papers in Oncology. Recurrent topics in Sarah Bernstein's work include Immunotherapy and Immune Responses (11 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Cervical Cancer and HPV Research (3 papers). Sarah Bernstein is often cited by papers focused on Immunotherapy and Immune Responses (11 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Cervical Cancer and HPV Research (3 papers). Sarah Bernstein collaborates with scholars based in United States, Poland and South Korea. Sarah Bernstein's co-authors include Samir N. Khleif, J. Michael Hamilton, Osama E. Rahma, Seth M. Steinberg, Mildred R. Chernofsky, G. Scott Rose, Barry L. Gause, Antoun Toubaji, Chad A. Hamilton and G. Larry Maxwell and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

Sarah Bernstein

19 papers receiving 521 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sarah Bernstein United States 11 303 298 186 68 66 19 538
Cheng-Tao Lin Taiwan 12 161 0.5× 168 0.6× 92 0.5× 102 1.5× 86 1.3× 21 462
Elizabeth M. Burton United States 14 112 0.4× 292 1.0× 169 0.9× 44 0.6× 51 0.8× 84 574
Bergerat Jp France 14 140 0.5× 125 0.4× 136 0.7× 60 0.9× 68 1.0× 42 536
Anders Kverneland Denmark 11 321 1.1× 290 1.0× 134 0.7× 23 0.3× 56 0.8× 19 573
Juergen Bukur Germany 11 390 1.3× 316 1.1× 223 1.2× 28 0.4× 34 0.5× 15 677
George Vlahos Greece 12 202 0.7× 274 0.9× 182 1.0× 241 3.5× 124 1.9× 22 663
Maria Spyropoulou‐Vlachou Greece 13 368 1.2× 138 0.5× 189 1.0× 65 1.0× 29 0.4× 26 676
Barbara Tringler Austria 11 358 1.2× 425 1.4× 91 0.5× 60 0.9× 152 2.3× 17 749
V. Fermeaux France 10 158 0.5× 400 1.3× 208 1.1× 142 2.1× 95 1.4× 30 847
Walter M. Klein United States 9 85 0.3× 325 1.1× 171 0.9× 29 0.4× 120 1.8× 13 568

Countries citing papers authored by Sarah Bernstein

Since Specialization
Citations

This map shows the geographic impact of Sarah Bernstein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sarah Bernstein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sarah Bernstein more than expected).

Fields of papers citing papers by Sarah Bernstein

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sarah Bernstein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sarah Bernstein. The network helps show where Sarah Bernstein may publish in the future.

Co-authorship network of co-authors of Sarah Bernstein

This figure shows the co-authorship network connecting the top 25 collaborators of Sarah Bernstein. A scholar is included among the top collaborators of Sarah Bernstein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sarah Bernstein. Sarah Bernstein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
2.
Rahma, Osama E., Sarah Bernstein, Seth M. Steinberg, et al.. (2014). Pre-immature dendritic cells (PIDC) pulsed with HPV16 E6 or E7 peptide are capable of eliciting specific immune response in patients with advanced cervical cancer. Journal of Translational Medicine. 12(1). 353–353. 26 indexed citations
3.
Rahma, Osama E., J. Michael Hamilton, Sarah Bernstein, et al.. (2014). The immunological and clinical effects of mutated ras peptide vaccine in combination with IL-2, GM-CSF, or both in patients with solid tumors. Journal of Translational Medicine. 12(1). 55–55. 59 indexed citations
4.
Rahma, Osama E., Malgorzata Czystowska, Marta Szajnik, et al.. (2011). A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients. Cancer Immunology Immunotherapy. 61(3). 373–384. 79 indexed citations
5.
Rahma, Osama E., Ramy Ibrahim, Antoun Toubaji, et al.. (2010). A pilot clinical trial testing mutant von Hippel-Lindau peptide as a novel immune therapy in metastatic Renal Cell Carcinoma. Journal of Translational Medicine. 8(1). 8–8. 25 indexed citations
6.
Stany, Michael P., et al.. (2010). Gemcitabine-Associated Large Vessel Vasculitis Presenting as Fever of Unknown Origin. JCR Journal of Clinical Rheumatology. 16(4). 181–182. 15 indexed citations
7.
Rahma, Osama E., Malgorzata Czystowska, Marta Szajnik, et al.. (2010). Abstract 2414: Comparable effect of p53 peptide vaccine in adjuvant or pulsed on dendritic cells in ovarian cancer patients: A gynecologic oncology group study. Cancer Research. 70(8_Supplement). 2414–2414. 1 indexed citations
8.
Toubaji, Antoun, Maurizio Provenzano, Robert J. Behrens, et al.. (2008). Pilot study of mutant ras peptide-based vaccine as an adjuvant treatment in pancreatic and colorectal cancers. Cancer Immunology Immunotherapy. 57(9). 1413–1420. 99 indexed citations
9.
Hamilton, Chad A., G. Larry Maxwell, Mildred R. Chernofsky, et al.. (2008). Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer. Gynecologic Oncology. 111(3). 530–532. 68 indexed citations
10.
Gause, Barry L., et al.. (2007). Phase II clinical trial of mutant Ras peptide vaccine in combination with GM-CSF and IL-2 in advanced cancer patients. Journal of Clinical Oncology. 25(18_suppl). 3067–3067. 2 indexed citations
11.
Elkas, John C., William E. Winter, Mildred R. Chernofsky, et al.. (2006). A phase I trial of oxaliplatin and topotecan in recurrent ovarian carcinoma. Gynecologic Oncology. 104(2). 422–427. 10 indexed citations
12.
Goy, André, Sarah Bernstein, Elliot Epner, et al.. (2005). Bortezomib in patients with relapsed or refractory mantle cell lymphoma (MCL): Preliminary results of the PINNACLE study. Journal of Clinical Oncology. 23(16_suppl). 6563–6563. 18 indexed citations
13.
Gause, Barry L., Sarah Bernstein, Frank Grollman, et al.. (2005). Autologous PBMCs pulsed with HPV16 E6 as an immunotherapeutic agent for patients with advanced cervical cancer. Journal of Clinical Oncology. 23(16_suppl). 2508–2508. 3 indexed citations
14.
Toubaji, Antoun, et al.. (2005). Immunotherapeutic role of mutant ras peptide-based vaccine as an adjuvant in pancreatic and colorectal cancer. Journal of Clinical Oncology. 23(16_suppl). 2573–2573. 1 indexed citations
15.
Forero, Andres, Sarah Bernstein, Francine Foss, et al.. (2005). Initial phase II results of SGN-30 (anti-CD30 monoclonal antibody) in patients with refractory or recurrent systemic anaplastic large cell lymphoma (ALCL). Journal of Clinical Oncology. 23(16_suppl). 6601–6601. 15 indexed citations
16.
Gause, Barry L., Susanne Steinberg, Frank Grollman, et al.. (2005). Pre-immature dendritic cells pulsed with human papillomavirus 16 E7 peptide vaccine in advanced cervical cancer. Journal of Clinical Oncology. 23(16_suppl). 2522–2522. 4 indexed citations
17.
Khleif, Samir N., Scott I. Abrams, J. Michael Hamilton, et al.. (1999). A Phase I Vaccine Trial with Peptides Reflecting ras Oncogene Mutations of Solid Tumors. Journal of Immunotherapy. 22(2). 155–165. 96 indexed citations
18.
Anderson, K. C., Jack W. Singer, Sarah Bernstein, et al.. (1998). NCCN practice guidelines for multiple myeloma. 12. 317–351. 3 indexed citations
19.
Bernstein, Sarah, et al.. (1981). A clinical study of stabilized 17D strain live attenuated yellow fever vaccine. Journal of Biological Standardization. 9(4). 445–452. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Cheng-Tao Lin Breakdown of academic impact, for papers by Elizabeth M. Burton Breakdown of academic impact, for papers by Bergerat Jp Breakdown of academic impact, for papers by Anders Kverneland Breakdown of academic impact, for papers by Juergen Bukur Breakdown of academic impact, for papers by George Vlahos Breakdown of academic impact, for papers by Maria Spyropoulou‐Vlachou Breakdown of academic impact, for papers by Barbara Tringler Breakdown of academic impact, for papers by V. Fermeaux Breakdown of academic impact, for papers by Walter M. Klein
Rankless by CCL
2026